

Index

0-9, and Symbols

3+3 “Up & Stop” design, 6–7

A

Abiraterone, 246, 265

Abiraterone (an antiandrogen), 258

Absolute neutrophil counts (ANC), 182, 185

Absorption

acid-reducing agent interaction,
267–272

high-fat food interaction, 259–265

non-high-fat meals, 265–267

Accelerated Titration Designs, 9–10

Acid-reducing agent interaction

cabozantinib, 271

ceritinib, 271

coadministration, 270

crizotinib, 272

dabrafenib, 271

DDI, 271, 272

drug interaction, 267

evaluation, 267–269

FDA reviewer, 270

gated approach, 271

H₂-blockers, 271

idelalisib, 270, 271

panobinostat, 270

PBPK, 270

pharmacometric analyses, 270

pH-dependent solubility, 267

ponatinib, 272

PopPK, 270

PPI, 271

PPIs, 267, 271

vandetanib, 270

vismodegib, 271, 272

Adaptive Randomization Design, 14–15

Ado-trastuzumab, 252

Ado-trastuzumab emtansine, 252, 307, 308

Afatinib, 255, 256

Akaike Information Criterion (AICc) score, 222

Alkylating agents, 198, 199

American Society of Clinical Oncology
(ASCO), 72

Anaplastic lymphoma kinase (*ALK*), 32

Angiogenesis inhibitors, 192, 200

Antibody–drug conjugates (ADCs), 55, 211

Anti-CD20 rituximab biosimilars, 182

Antimicrotubule agents, 197

Antimitotics, 212

Antitumor agents, 228

Antitumor efficacy, 131–133

Approval database, FDA

Breakthrough Therapy Designation, 240

CDER, 239

Drugs@FDA, 239

formulation and route of administration,
246–247

oncology therapeutics, 240–245

patients/healthy volunteers, 240–246

priority review, 240

Arsenic trioxide, 78, 82

Axitinib, 140, 141, 248, 295, 296

B

Bayesian designs, 11, 13

BCR-ABL transcript levels, 228

Belinostat, 252

- Beta-adrenergic positive tumors, 195
 - Beta-III tubulin isotypes, 195
 - Bevacizumab, 195
 - BiaCore[®], 181
 - Binocrit[®] (epoetin alfa), 184
 - Biochemical model, 216
 - Biologics, dose selection strategies
 - antibody-drug, 250
 - clinical pharmacology, 251
 - dose- and exposure-response, 250
 - dose and regimen justification, 250
 - exposure-response, 250
 - ipilimumab, 251
 - monoclonal antibodies, 250
 - MTD, 250
 - nivolumab, 250
 - pembrolizumab, 250
 - pertuzumab, 251
 - PFS, 251
 - protein drugs, 250
 - therapeutic index, 250
 - Biomarkers, pharmacology
 - ALK, 32
 - breast cancer, 32
 - colon cancer, 31
 - EGFR signaling pathway, 31
 - lung cancer, 32–33
 - measurement, 33–34
 - predictive marker, 30
 - predictive” and “prognostic” factors, 30
 - prognostic biomarkers, 30
 - Biosimilar assessment
 - analytical considerations, 179, 181
 - definition, 178
 - design space, 177
 - guidance, 178–179
 - in EU, 180
 - noninferiority studies, 179
 - physicochemical and purity profiles, 176
 - PK/PD studies, 182
 - recombinant therapeutic proteins, 176
 - sensitive analytical testing, 176
 - structural modifications, 176
 - therapeutic IgG1/antibody, 177
 - Blinatumomab, 289, 290
 - Bluetooth-enabled ECG recording devices, 97
 - Body surface area (BSA), 41
 - cyclophosphamide, 61
 - human blood volume, 60
 - methotrexate, 61
 - MTD, 61
 - pharmacokinetic parameters, 61
 - pharmacokinetic rationale, 62–64
 - therapeutic dose, 60
 - Bootstrap analyses, 217
 - Bortezomib, 252
 - Bosutinib, 263, 292, 295
 - BRAF* V600K or V600E mutations, 152
 - Breakthrough therapy, 112
 - Breakthrough Therapy Designation, 111, 238, 240
 - Breast cancer, 32
 - Brentuximab vedotin, 252
- C**
- Cabazitaxel, 252
 - Cabozantinib, 246, 248, 254, 265, 271
 - Calvert formula
 - AUC, 71
 - chemotherapy experience, 71
 - concentration-time profiles, 71
 - GFR, 71
 - Cancer, 213–216
 - cell lines, 212
 - clonal diversity, 211, 212
 - Darwinian evolution, 211, 213
 - deep sequencing technology, 211
 - differential survival, clones upon treatment, 211, 212
 - mutational spectra, 212
 - options and limitations
 - biochemical model, 216
 - cell biological models, 216
 - Gompertz model, 213
 - IACUC guidelines, 213
 - in vivo xenograft setting, 213
 - mechanistic data, 216
 - microenvironmental models, 216
 - Simeoni model, 213
 - tumor kinetic model schematics and equations, 213–216
 - polyclonal disease, 212
 - stochastic disease progression, 212
 - stochastic progression, 211
 - xenograft tumors, 212
 - Cancer Cell Line Encyclopedia (CCLE)
 - project, 154
 - Cardiac arrhythmias, 80
 - Cardiac repolarization, 98
 - Cardiac safety Research Consortium (CSRC), 90
 - Carrying-capacity-limited growth, 213
 - CD133+ precursor cells, 193
 - Cell biological models, 216
 - Center for Devices and Radiological Health (CDRH), 117
 - Center for Drug Evaluation and Research (CDER), 111, 239

- Ceritinib, 91, 99, 246, 254, 263, 264, 271
 Change in tumor size (CTS), 225, 227
 Chemotherapy, 238
 CHOP regimen, 252
 Chou–Talalay method, 155
 Chronic lymphocytic leukemia, 270
 Chronic myeloid leukemia (CML), 154, 228
 Claret/Bruno TGI model, 230, 231
 Classic ICH E14-type model, 86
 Clinical trials, QTc assessment
 - arrhythmic events, 101
 - ECG acquisition, 97
 - formal analysis, 83
 - post-approval phase, 80
 - preapproval, 78, 94
 - thorough DQT, 95
 Colorectal carcinoma, 226
 Combination drugs
 - development, 155
 - in vivo models, 156
 - RNA sequence libraries, 168
 Combination therapy
 - acute childhood leukemia, 152
 - clinical development, 160
 - clinical pharmacology, 166–167
 - codevelopment, 159
 - imatinib, 152
 - in vitro assessment, 153–155
 - in vivo assessment, 156, 158
 - linear pathway, 152
 - phase 1, 160–164
 - phase 2 and 3, 164–165
 - preclinical development, 153
 - preclinical safety, 158–159
 - targeted therapies, 152
 - trastuzumab, 152
 - tyrosine kinase inhibitors, 152
 Complete Response (CR), 228
 Comprehensive in vitro Proarrhythmia Assay (CiPA), 80
 Concentration-QTc (C-QTc)
 - advantages, 85, 98, 99
 - applications, 85
 - cardiac repolarization, 98
 - ceritinib, 99
 - ECG data, 89
 - estimation, 99
 - exposure-QTc response, 79
 - exposure-response modeling, 86
 - false positive outcome, 98
 - FDA, 91, 99
 - FDA's QT-IRT group, 98
 - hERG channel trafficking, 99
 - ICH E14 Q&A R3 document states, 96
 - ICH regulators, 98
 - implementation, E14 guidance, 79
 - IQ-CSRC study, 91
 - IUT, 98
 - linear modeling, 99
 - LME model, 98, 100
 - magnitude of QTc effect, 99
 - nonlinear PK/PD models, 99
 - regulatory reviews, TQT study, 98
 - relationship, 89
 - sample sizes, 99
 - simulate/predict effects, 99
 - single observation in statistical, 96
 - single or multiple studies, 92
 - sufficient data, 100
 - tests for hysteresis, 99
 - vandetanib, 99
 Continual reassessment method (CRM), 11
 Conventional cytotoxic agents, 48
 Cox model, 306
 Crizotinib, 272
 Cycle 1 chemotherapy, 185
 Cyclophosphamide, 199
 CYP3A4 enzyme, 166–167
 Cytochrome P450 iso-enzymes, 166
 Cytotoxic agents, 2, 238, 239
 Cytotoxic drugs, 248
 Cytotoxics, dose selection strategies
 - ado-trastuzumab emtansine, 252
 - belinostat, 252
 - brentuximab vedotin, 252
 - cabazitaxel, 252
 - cell proliferation and maturation, 251
 - CHOP regimen, 252
 - FDA request, 252
 - HDAC inhibitors, 251, 252
 - panobinostat, 252
 - post-marketing request, 253
 - post-marketing requests, 252
 - post-marketing study, 252
 - romidepsin, 252
- D**
- Dabrafenib, 166, 271
 Dabrafenib pharmacokinetics and pharmacodynamics, 258
 Darwinian evolution, 211, 213
 Dasatinib, 135
 Data-mining approach, 211
 Deep sequencing technology, 211
 Definitive QTc (DQTc)
 - design, 87
 - ECG study, 86

- Definitive QTc (DQTc) (*cont.*)
 ECGs, 89
 in oncology, 86, 90, 92
 pivotal trial in cancer patients, 88
 preclinical cardiac safety pharmacology, 102
 small sample sizes, 91
 thorough, 87–89, 93–96, 99, 100
- Density-independent fitness, 217
- Digoxin, 195
- Dinutuximab, 248
- Disease-free survival (DFS), 18
- Dose and regimen identification, 250–259
 characterizing exposure–response,
 248–250
 cytotoxic drugs, 248
 development of oncology agents, 247
 dose selection strategies
 biologics, 250–251
 cytotoxics, 251–253
 first-in-human trials, 247
 ipilimumab, 247
 MTD, 247
 non-cytotoxic targeted agents
 (*see* Non-cytotoxic targeted agents)
 OBD, 247
 omacetaxine, 247
 post-marketing commitments, 247
 radium-223, 247
- Dose selection strategies
 biologics, 250–251
 cytotoxics, 251–253
- Dose-limiting toxicity (DLT), 95, 96
- Dosing
 and schedules, 196
 computational pharmacology, 194
 D1–D2–D4 basis, 194
 drug discovery, 59
 levels, 193
 P450 inhibitor, 198
 pharmacokinetics and oncology, 64–67
 pharmacometric approach, 67–69
 PK, 197
- Drug development
 ADME studies, 166
 anticancer agents, 153
 ectopic and orthotopic xenograft, 156
 efficacy, 156
 oncology, 163
 PK, 153
 predictive value, 153
- Drug repositioning (DR), 190
- Drug-related proarrhythmia, 79
- Drug-resistant clone, 219, 220
- Drug-sensitive clone, 219, 220
- Durable response model, 221
- Duration of response (DoR), 165
- E**
- Electrocardiogram (ECG) assessment
 ceritinib, 91
 classic ICH E14-type development
 program, 86
 C-QTc modeling, 92
 C-QTc relationship, 89
 dedicated QTc study, 89
 development programs, 94
 dose reduction, 94
 DQT study, 86
 drug classification, 87
 drug development plan, 85
 FDA, 93
 flexibility and frequent assessment, 94
 front-loaded development program, 89–92
 full-development program, 92–94
 HDAC, 85
 healthy-volunteer thorough DQT study, 88
 IQ-CSRC study, 91
 Late Phase (Phase 3) development, 89
 late-phase trials, 91
 monitoring, 87
 MTD, 90
 nonclinical ADME, 87
 nonclinical cardiovascular safety testing, 86
 PK exposures, 88
 POC study, 94
 ponatinib, 91
 pooling of data, 92
 positive control, 88
 preapproval clinical trials, 94
 preapproval oncology trials, 85
 predose, 90
 proarrhythmic risk, 87
 proof-of-concept study, 90
 RD, 90
 registration trials, 94
 RTK inhibitors, 85
 safe and cost-effective, 91
 serial time-matched baseline, 91
 single-/multiple-dose trials, 86
 sponsor financial resources, 92
 stress, 94
 suprathreshold doses, 88
 thorough DQT study, 87–89
 Vandetanib, 93
 Vismodegib, 87
- Electrolyte imbalance, 95
- Emax models, 94

- Enzalutamide, 246, 258, 259
- Epidermal growth factor receptor (EGFR, 31
- Erlotinib, 141
- European Medicines Agency (EMA), 159, 183, 267
- Everolimus (EVR), 264, 295, 309
- Evolutionary dynamics model, 228
- clinical development
 - antitumor agents, 228
 - CR, 228
 - PD, 228
 - PR, 228
 - RECIST, 228
 - SD, 228
 - SLD, 228
 - population biology model, 216
 - small-molecule drugs, 216
 - tumor kinetic (*see* Tumor kinetic modeling)
 - xenograft studies, 217–218
- Evolutionary model parameters, 224
- Expedited access PMA (EAP) program, 117
- Expedited Programs for Serious Conditions—Drugs and Biologics, 118
- Exposure-QTc response, 79
- Exposure-Response (E-R) analyses, 252
- case–control studies, 306
 - count-annualized relapse, 304
 - dosing recommendation, 303
 - drug efficacy, 308
 - noninferiority trial, 308, 310
 - pairwise comparisons, 304
 - pharmacokinetics, 304
 - phase 3 trials, 304
 - regulatory setting, 305
 - subgroup analysis, 311, 312
- Exposure–response relationship, 248–250
- F**
- Familial adenomatous polyposis (FAP), 31
- FDA Clinical Pharmacology reviewer, 256
- FDA Guidance for Industry, 272
- FDA Safety and Innovation Act (FDASIA), 110
- FDA’s QT-IRT group, 98
- Filgrastim, 185
- Financial considerations, 85
- First in human (FIH) studies, 153
- anti-cancer drug, 40
 - cytotoxic agents, 47–50
 - EMA guideline, 47
 - NOAEL Approach, 41–44
 - Regulatory Guidance, 41–46
 - STD10 and HNSTD approaches, 40
 - TGN1412, 46
- First-In-Human Clinical Trials, 5–12
- Fixed doses, 60
- Fixed-dose combinations, 159
- fluorouracil (5-FU), 2
- Food and Drug Administration (FDA), 304
- and alignment, 112
 - application of processes, 298
 - Approval Letter, 239
 - approval paths, 109
 - biologic license, 111
 - biomedical innovation, 109
 - biopharmaceutics, 297
 - Breakthrough Therapy Designation, 238
 - breakthrough therapy designation program, 113
 - CDER Manual, 119
 - Clinical Pharmacology, 297
 - Clinical Pharmacology review, 257
 - Clinical Pharmacology reviewer, 256
 - CMC components, 116
 - CMC development, 115
 - codevelopment, drug, 116
 - collaboration, 240
 - communication, 240
 - daclatasvir, 118
 - drug development, 115
 - Drugs@FDA database, 239
 - efficacy/safety, 113
 - expectations, 115
 - expedited programs, 108
 - exposure–response analyses, 248
 - exposure–response analysis, 252
 - FDASIA and PDUFA V legislation, 118
 - feasibility and reproducibility issues, 109
 - food-effect guidance, 265
 - guidance, 240
 - Guidance for Industry, 272
 - interaction, 240
 - interactive communication, 115
 - new oncology therapeutics, 241–245
 - oncology drugs approved, 240
 - oral oncology agents, 260
 - phase 1-2-3 process, 110
 - prioritization, 118
 - public health priorities, 119
 - review, 251
 - reviewer’s independent analysis, 296
 - reviewer’s independent central tendency analysis, 296
 - reviewers, 248, 270, 271, 291
 - and sponsors, 110, 252
 - targeted therapies, 109

Food and Drug Administration (FDA) (*cont.*)
 therapy designation, 110
 time period, 240
 website, 239

Food and Drug Administration Modernization Act (FDAMA), 109

Fridericia's correction (QTcF), 97

Front-loaded development program, 89–92

G

Garbage-in-garbage-out (GIGO) variety, 211

GastroPlus®, 270

Gazyva®, 111, 112, 240

Gefitinib, 312

Gemcitabine, 312–313

Genomic biomarkers, 19

Glomerular filtration rate (GFR), 71

Gompertz model, 213

Granulocyte colony-stimulating factor (G-CSF), 185

Growth rate-based estimate of T/C, 217

H

H2-blockers, 271

Hazard ratio, 226

Hedgehog medulloblastoma, 195

Heparin-induced thrombocytopenia (HIT), 314

High-fat food interaction

- abiraterone, 265
- administering drugs, 264
- bosutinib, 263
- cabozantinib, 265
- ceritinib, 263, 264
- and characterization, 260–262
- coadministration, 259
- drug absorption and pharmacokinetic variability, 260
- drugs measurement, 263
- everolimus, 264
- ibrutinib, 264, 265
- oral oncology agents, 260
- oral oncology drugs, 260
- orally administered drug, 259
- palbociclib, 264
- panobinostat, 264
- pomalidomide, 263, 264
- post-marketing clinical study, 263
- regorafenib, 263, 264
- specification-limit, 260
- vemurafenib, 263, 264

Histone deacetylase (HDAC) inhibitors, 85, 251, 252

Hodgkin lymphoma, 2

Holter monitoring, 97

HT1080 fibrosarcoma-bearing rats, 198

Human equivalent dose (HED), 162

Human ether-a-go-go-related gene (hERG) potassium channels, 84

Hypertension, 152

I

Ibrutinib, 246, 247, 257, 264, 265, 294

ICH regulators, 98

ICH S7A, 80

ICH S7B, 80

Idelalisib, 257, 270, 271, 295

Imatinib, 133–135

Immunoglobulin (IgG)-based therapeutics, 176

Immunotherapies, 238

In vitro companion diagnostic (IVD), 117

Iniparib, 313

Innovation Quality (IQ) Consortium, 90

Institutional Animal Use and Care Committee (IACUC) guidelines, 213

Institutional review boards (IRBs), 82

Intersection–union test (IUT), 89, 98, 99

Investigational Device Exemption (IDE) applications, 117

Investigational New Drug Application (IND), 4–5

Ipilimumab, 247, 251, 290

Irinotecan, 196

K

Kaplan–Meier curves, 254, 307

Ketoconazole, 295

L

Lenvatinib, 142, 248, 254, 292, 295

Leukemia, 239

Light-meal, 267

Linear mixed effects (LME) models, 98

Liver transaminases (AST and ALT), 289

Lung Cancer, 32–33

M

MABEL Approach, 44

Mammalian target of rapamycin (mTOR), 155

Mantle cell lymphoma (MCL), 257

Mathematical modeling, 210

Maximally tolerated dose (MTD), 190, 254–259

- non-cytotoxic, small molecule targeted
 - agents approved at benefit–risk ratio, 254
 - cabozantinib, 254
 - ceritinib, 254
 - dose-optimization, 254
 - lenvatinib, 254
 - ponatinib, 255
 - post-marketing evaluation, 254
 - vandetanib, 254
 - non-cytotoxic, small molecule targeted
 - agents approved below
 - afatinib, 255, 256
 - compounds, 255
 - Dabrafenib pharmacokinetics and pharmacodynamics, 258
 - dose-escalation study for trametinib, 257
 - enzalutamide, 258, 259
 - FDA Clinical Pharmacology reviewer, 256
 - ibrutinib, 257
 - idelalisib, 257
 - MCL, 257
 - pazopanib, 256
 - PBPK model, 259
 - PK/PD modeling, 255
 - QD regimen, 256
 - QW and QD regimens, 259
 - renal cell carcinoma, 256
 - vismodegib, 256
 - Maximum administered dose (MAD), 51
 - Maximum target inhibition (MTI), 11
 - Maximum tolerated dose (MTD), 60, 237
 - antitumor therapy, 163
 - assay sensitivities, 162
 - clinical pharmacology, 162
 - codevelopment, 160
 - concentration–effect relationship, 163
 - dose-escalation methods, 160
 - dose–toxicity probability curves, 161
 - historical data, 162
 - in vitro/in vivo cell assays, 163
 - model-based designs, 161
 - phase 1 trials, 161
 - PI3K/AKT/mTOR, 162
 - QTc assessment, 81
 - RP2D dose, 161
 - rule-based designs, 160
 - safety and PK, 160
 - systemic exploration, 162
 - Mechanistic data, 216
 - Mechanistic insights, 211
 - Medical Policy Council (MPC), 115
 - Medullary thyroid cancer (MTC), 304
 - Metastatic gastric cancer (mGC), 306
 - Methotrexate, 2
 - Metronomic chemotherapy (MC), 190
 - Metronomics
 - administration, 190
 - antiangiogenic paradigm, 191
 - antiangiogenic properties, 190
 - antiangiogenic therapies, 194
 - chemotherapy, 194–195
 - doses, 193–194
 - drug repositioning, 190
 - mechanisms of action, 193
 - personalized therapy, 194
 - pharmacogenetics, 199, 200
 - pharmacogenomics, 199, 200
 - phase I/II studies, 196
 - progression, 190
 - proimmune properties, 192
 - thrombospondin 1, 195
 - tumor initiating cells, 192
 - Microenvironmental models, 216
 - Mismatch repair deficiency (dMMR), 31
 - Model-fitted estimate of T/C (treated/control growth), 217
 - Modification of Diet in Renal Disease (MDRD) equation, 71
 - Molecularly targeted agent, 40
 - Monoclonal antibodies (mAbs), 52, 64, 65, 84
 - Moxifloxacin, 81
 - Myelogenous leukemia, 3
- N**
- Nab-Paclitaxel, 312–313
 - National Cancer Institute (NCI) CTCAE, 95
 - National Cancer Institute (NCI) organ dysfunction working group, 272
 - National Cancer Institute 60 (NCI60), 153
 - National Health and Nutrition Examination Survey (NHANES), 69
 - Neoplastic disease, 81
 - Neupogen[®], 185
 - Neutropenia, 253
 - New molecular entities (NMEs), 126
 - Nivolumab, 250
 - NLME mixture modeling, 228
 - NOAEL approach, 43
 - Non-antiarrhythmic drugs, 77–78
 - Nonclinical ADME, 87
 - Nonclinical cardiovascular safety testing, 86
 - Non-cytotoxic targeted agents, 254–259
 - exposure–response relationship, 248–250, 253
 - pharmacokinetic data, 253

- Non-cytotoxic targeted agents (*cont.*)
 single dose and regimen, 253
 small molecule
 below MTD, 255–259
 MTD, 254–255
- Non-high-fat meals
 axitinib, 267
 compositions, various meal types, 265, 266
 idelalisib, clinical pharmacology studies
 for, 267
 and light-meal, 267
 macronutrient distribution ranges, 265
 moderate-fat and low-fat, 265
 sponsor, everolimus, 267
 vismodegib, 267
- Non-Hodgkin's lymphoma, 270
- Nonlinear mixed effects (NLME)
 framework, 222
- Nonlinear relationship, 311
- Non-small cell lung cancer (NSCLC), 109
- Nutrient-limited growth, 218
- O**
- Obesity, 72
- Objective response rate (ORR), 305
- Ofatumumab, 65, 294
- Olaparib, 246, 248, 295
- Omacetaxine, 247
- Omnitrope[®], 178
- Oncology
 animal models, 156
 biomarkers, 314
 combination chemotherapy, 152
 dose reductions, 159
 drug development, 156
 pharmacodynamics markers, 314
 phase 1, 160–164
 Tbo-filgrastim (Granix), 313
- Oncology drug development
 biologic therapies, 3–4
 chemotherapy, 2
 EGFR mutations, 3
 Two-Stage Designs, 13
- Optimal biological dose (OBD), 163, 247
- Organ impaired populations
 blinatumomab, 290
 bosutinib, 292
 clinical pharmacokinetic data, 290
 clinical studies, 272
 compounds, 291
 creatinine clearance, 290
 definitions, 272
 evaluation, 272–288
 FDA Guidance for Industry, 272
 hepatic, 272, 289
 idelalisib, 291
 inclusion and exclusion criteria, 292
 ipilimumab, 290
 lenvatinib, 292
 liver transaminases (AST and ALT), 289
 monoclonal antibodies, 289
 ponatinib, 291
 PopPK assessments, 272
 population pharmacokinetic assessment,
 289, 290
 post-marketing request, 291
 ramucirumab, 290
 renal, 272
 renal impairment, 292
 safety data, 291
 small molecules, 291
 sponsors, 289
 TB, 289
 vandetanib, 292
- Other People's Data (OPD), 211
- Overall response rate (ORR), 165
- Overall survival (OS), 165, 177, 224
- P**
- Paclitaxel, 198
- Palbociclib, 264, 296
- Panobinostat, 248, 252, 264, 270
- Parsimonious models, 211
- Partial Response (PR), 228
- Patient-derived tumor xenografts (PDTX), 156
- Patient-reported outcomes (PROs), 17
- Pazopanib, 247, 256
- PBPK model, 270
- Pediatrics, 72–73
- Pembrolizumab, 250
- Personalized medicine, 18
- Pertuzumab, 251
- Pharmaceutical Researchers and
 Manufacturers of America
 (PhRMA), 118
- Pharmacodynamics (PD), 153, 163
 assessments, 182
 biosimilars, 181–183
 in drug development, 182
 evaluations, 184
 markers, 183–185
 multiple dose levels, 183
 therapeutic mAbs, 184
- Pharmacokinetic/pharmacodynamic (PK/PD)
 relationships, 157
- Pharmacokinetics (PK), 153, 195–199

biosimilars, 181–183
 drug interactions, 80
 Pharmacometrics, 210
 Phase 0 Clinical Trials, 5
 Phase 2 doses (RP2D), 196
 phase I clinical trials, 6
 Phase Ib Combination Trial Designs, 12
 Phase I-Phase II-Phase III, 238
 Phosphatidylinositol 3-kinase (PI3K), 155
 Physiologically based pharmacokinetic (PBPK) model, 259, 270
 Pictilisib (GDC0941), 129
 PKPD models
 drug exposure-biomarker, 126–127
 exposure-antitumor effect relationships, 127–128
 PK-tumor kinetic modeling, 218
 Polyclonal disease, 212
 Pomalidomide, 248, 263, 264
 Ponatinib, 91, 248, 255, 272, 291
 Population pharmacokinetic (PopPK) assessments, 272
 Population pharmacokinetic assessment, 289, 290
 Population-specific correction method, 97
 Post-marketing requirement (PMR), 119, 306
 Practical challenges, oncology clinical pharmacology, 247–272
 absorption (*see* Absorption)
 approval database, 239–247
 benefit–risk ratios, 238
 Breakthrough Therapy Designation, 238
 chemotherapy, 238
 clinical safety, 237
 cytotoxic agents, 238, 239
 drug treatments, 238
 FDA Breakthrough Therapy Designation, 238
 identification of dose and regimen (*see* Dose and regimen identification)
 immunotherapies, 238
 indication selection, 238
 industrial, 239
 leukemia, 239
 MTD, 237
 optimizes dose and regimen, 238
 organ impaired populations, 272–293
 pharmacokinetics, 238
 Phase I-Phase II-Phase III, 238
 phase-based mentality in drug development, 238
 QTc prolongation, 293–297
 safety, 237, 238
 tolerability, 237

Practical considerations, QTc assessment
 Bluetooth-enabled ECG recording devices, 97
 clinical trials, 95
 C-QTc, 96
 digital ECG data, 96
 DLT, 95, 96
 ECG, 96, 97
 electrolyte imbalance, 95
 FDA, 96
 Fridericia’s correction (QTcF), 97
 heart rate, 97
 Holter monitoring, 97
 inclusion/exclusion criteria, 95
 measurement, QTc interval, 95
 NCI CTCAE, 95
 population-specific correction method, 97
 rigorous control and standardization, 96
 thorough DQT study, 96
 TQT study, 96
 Predictive Marker, 30
 Prescription Drug User Fee Act (PDUFA), 107
 Primary efficacy variable, 246
 Proarrhythmic effects, 80, 84
 Proarrhythmic risk, 87
 Prognostic biomarkers, 30
 Progression-free survival (PFS), 16, 119, 165, 177, 246
 Progressive Disease (PD), 228
 Proof-of-concept study, 90
 Prophylactic G-CSF, 253
 Protein tyrosine kinases (PTKs)
 “druggable” targets, 122
 transduction pathways, 122
 Proton pump inhibitors (PPIs), 267, 271

Q

QTc assessment, 81–94, 98–100, 293–297
 anticancer agent for proarrhythmic effect, 80
 anticancer agents, 80
 cancer types, 80
 cardiac arrhythmias, 80
 characterization, 78
 CiPA, 80
 clinical
 benefit/risk ratio, anticancer agent, 84
 C-QTc modeling, 84
 development plan, 83
 development program, 84
 ECG testing, 84
 financial considerations, 85
 hERG potassium channels, 84

- QTc assessment (*cont.*)
- monoclonal antibodies, 84
 - pharmaceutical Sponsors of oncology trials, 83
 - proarrhythmic effects, 84
 - sample sizes, 84
 - size and class of molecule, 84
 - sponsors, 83
 - clinical assessments, 80
 - clinical ECG assessment, 79
 - concentration (*see* Concentration-QTc (C-QTc))
 - C-QTc analysis, 79
 - differences and challenges
 - arsenic trioxide, 82
 - cancer patients, 82
 - clinical development practices, 81
 - clinical trials, 81
 - ECGs, 81
 - healthy volunteers, 81
 - ICH E14 guidance, 81
 - IRBs, 82
 - moxifloxacin, 81
 - MTD, 81
 - placebo treatments, 81
 - population characteristics, 81
 - positive control, 81
 - REMS, 83
 - supratherapeutic doses, 81
 - vandetanib, 82
 - drug-related proarrhythmia, 79
 - ECG, 78
 - ECG testing, 79
 - exposure-QTc response, 79
 - ICH E14 guidance, 79
 - ICH S7A, 80
 - ICH S7B, 80
 - outcome, 100–101
 - practical considerations, 94–97
 - preclinical testing and culminating, 78
 - preclinical testing, proarrhythmic effect, 80
 - proarrhythmic effect, 80
 - prolongation
 - analysis and collection of data, 293
 - axitinib, 295, 296
 - bosutinib, 295
 - clinical pharmacology objectives, 293
 - clinical safety data, 293, 295
 - concentration-dependent, 296
 - dedicated TQT studies, 295
 - drug concentrations and ECG parameters, 294
 - drug interaction/food effect studies, 295
 - ECG information, 296
 - everolimus, 295
 - exposure-QTc analysis, 296
 - exposure–response analysis, 296
 - FDA reviewer’s independent analysis, 296
 - FDA reviewer’s independent central tendency analysis, 296
 - guidelines, 293
 - ibrutinib, 294
 - ICH-E14 guideline, 294
 - idelalisib, 295
 - lenvatinib, 295
 - ofatumumab, 294
 - olaparib, 295
 - palbociclib, 296
 - post-marketing commitment, 294
 - radium-223, 294
 - REMS, 297
 - romidepsin, 294
 - sponsor ponatinib, 294
 - TQT studies, 293
 - TQT study, 293
 - vandetanib, 297
 - vismodegib, 295
 - torsade de pointes (TdP), 78
 - TQT study, 79
 - tyrosine kinase inhibitors, 80
 - Quantitative models
 - disease progression, 210
- R**
- Radium-223, 247, 294
 - Ramucirumab, 290, 308
 - Randomized Phase II Design, 14
 - Real-time video microscopy, 212
 - Receptor tyrosine kinase (RTK) inhibitors, 85
 - Recommended dose (RD), 90
 - Recommended phase 2 dose (RP2D), 5, 160
 - Regorafenib, 246, 263, 264
 - Regulatory
 - and drug development scientists, 238
 - drug and placebo, 295
 - expectations, 239, 297
 - Renal cell carcinoma, 256
 - Response Evaluation Criteria In Solid Tumors (RECIST) disease progression, 218
 - Rheumatoid arthritis (RA), 183
 - Risk Evaluation and Mitigation Strategy (REMS), 83, 297
 - Rituximab, 3
 - Rolling Six Design, 10
 - Romidepsin, 251, 252, 294
 - ROS oncogene 1 (ROS1), 130

S

Simcyp[®], 270
 Simeoni model, 213
 Size-based dosing
 in obesity, 72
 in pediatrics, 72–73
 Small molecule targeted agents, 254–255
 non-cytotoxic MTD, 254–255
 Small-molecule tyrosine kinase inhibitors, 84
 Somatic cell mutations, 212
 Sovaldi[®], 118
 Stable Disease (SD), 228
STD10, 42, 44–46, 49
 Steady-state exposure, 246
 Subependymal giant-cell astrocytoma
 (SEGA), 314
 Sum of the longest diameters (SLD), 228
 Sunitinib, 135, 136, 138, 139
 Supratherapeutic doses, 81, 88

T

Target-mediated drug disposition (TMDD), 306
 Temozolomide, 199
 Therapeutic and supratherapeutic doses, 86–87
 Therapeutic index, 250
 Thorough DQT study, 87–89, 91, 93–96, 99, 100
 Thorough QTc (TQTc)
 advantage, 100
 cardiac arrhythmia, 81–82
 classic design, 78
 in clinical development, 79
 digital ECGs, 96
 drug characteristics, 87
 ECG schedules, 89
 IUT analysis, 98
 methodology, 78
 outcome, 101
 placebo-controlled study, 87
 preclinical and clinical development, 78
 regulatory authorities, 90, 91
 regulatory reviews, 98
 serial ECG monitoring, 85
 standard, 79, 88
 structured ECG monitoring, 78
 UIT analysis, 100
 Time to growth (TTG), 224, 225
 Time to progression (TTP), 165
 Time-to-treatment failure (TTF), 18, 228
 Tropicam, 197
 Torsade de pointes (TdP), 78, 80, 87, 101
 Total bilirubin (TB), 289
 Total body weight (TBW), 60
 Toxic dose low (TDL), 51
 Trametinib, 166, 257

Translational pharmacology, 122–126
 Trastuzumab, 306
 Tumor cell killing, 52
 Tumor growth modeling, 216–229
 ADCs, 211
 cancer, 211–216
 cancer biology, 210
 data-mining approach, 211
 drug discovery and development setting, 211
 evolutionary dynamics (*see* Evolutionary
 dynamics model)
 Frequent Clone, 230
 GIGO variety, 211
 HIV infection, 210
 Kinetic Model Formulations, 230–231
 mathematical modeling, 210
 mechanistic insights, 211
 OPD, 211
 parsimonious model, 211
 perception, 210
 pharmacometrics, 210
 PK replaced with Cave/AUC, 229
 quantitative models, disease progression, 210
 Resistant Clone, 230
 Tumor kinetic modeling, 219, 221–227
 burden time course, 218
 clinical datasets, 228
 clonal compartments, 219
 drug concentration, 218
 drug-resistant clone, 219, 220
 drug-sensitive clone, 219, 220
 exponential growth, 218
 folding, 218
 growth/shrinkage rate, 219
 measurements, 218
 parameter identifiability
 AICc score, 222
 durable response model, 221–224
 exposure-growth function, 221
 full two-population model, 222–224
 growth rate of sensitive cells falls, 222
 NLME framework, 222
 primary resistance curve, 219
 primary resistance model, 221–224
 sensitivity analysis, 222–224
 settings and counts, 222
 tumor trajectories to parameter space, 221
 PK, 218
 RECIST disease progression, 218
 survival benefit
 and RECIST response criteria, 226
 CTS, 225, 227
 evolutionary model parameters, 224
 hazard ratio, 226
 HR calculation, 226, 227

- Tumor kinetic modeling (*cont.*)
OS, 224, 226
sensitive clone, 226
sensitivity analysis, HR, 227
true day of death, 225
TTG, 224, 225
tumor size, 224
tumor size-based time of death, 225
tumor size assessments, 219
- Tyrosine kinase inhibitors (TKIs), 80
cardiovascular safety, 142, 143
PKPD, 128–130
- U**
“Up-and-Down” designs, 7
US Food and Drug Administration (FDA),
152, 178
- V**
Vandetanib, 82, 93, 99, 254, 270, 292, 297
Vemurafenib, 263, 264
- Vinorelbine, 197
Vismodegib (Erivedge®), 87, 109, 246, 256,
267, 271, 272, 295
- X**
Xenograft
advantages, 217
bootstrap analyses, 217
exponential model, 217
growing and shrinking
clones, 217
growth rate-based estimate of T/C, 217
model-fitted estimate of T/C
(treated/control growth), 217
nutrient-limited growth, 218
pharmacokinetic (PK) model, 218
population biology, 217
short-term experiments, 217
- Z**
Zarxio®, 184–186